The 2018 Undoing Aging Conference, co-hosted by SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, is a scientific forum focused on the cellular and molecular repair of age-related damage. It provides a platform for leading researchers from around the world to share their work in stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery.
Each year Syracuse’s economic development counsel and chamber of commerce, CenterState CEO, recognizes Central New York businesses for their outstanding achievements during the past year. Ichor Therapeutics, Inc. has been selected as a finalist for 2018.
Kelsey Moody was a medical student at Upstate Medical University when he landed a $540,000 research grant and set up his own pharmaceutical research company.
Aaron Wolfe expects to finish up his Ph.D. in physics this semester. He has been working on his doctorate since 2011 and should have been done by now, he says, but a few things have gotten in the way—like helping to run a company, Ichor Therapeutics, of which he is chief operating officer.
One Central New York start-up is looking to start human trials on their solution to macular degeneration– a disease that’s a leading cause of vision loss for over 10 million Americans.
Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many as 15 million Americans and millions more globally. AMD has a significant impact on an individual’s quality of life through decreased independence and increased fall risk as well as the psychological and financial burden that vision loss can cause.
Ichor Therapeutics, a local biotechnology company focusing on therapeutic interventions for age-related disease, receives $1.35 million in new funding — including $1 million from European investors — and begins a 4-fold expansion of research capabilities in LaFayette, NY to engage in FDA compliant pre-clinical research.